147 related articles for article (PubMed ID: 24761212)
1. Cost-utility analysis of treatments for stage IB cervical cancer.
Katanyoo K; Praditsitthikorn N; Tangjitgamol S; Manusirivithaya S; Supawattanabodee B
J Gynecol Oncol; 2014 Apr; 25(2):97-104. PubMed ID: 24761212
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of adjuvant chemotherapy after concurrent chemoradiation in patients with locally advanced cervical cancer.
Rongsriyam K; Tangjitgamol S; Leelahavarong P; Teerawattananon Y; Tharavichitkul E; Tovanabutra C; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara LCA; Hanprasertpong J; Khunnarong J; Chottetanaprasith T; Lorvidhaya V
J Med Imaging Radiat Oncol; 2020 Dec; 64(6):873-881. PubMed ID: 32978901
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer.
Katanyoo K; Chitapanarux I; Tungkasamit T; Chakrabandhu S; Chongthanakorn M; Jiratrachu R; Kridakara A; Townamchai K; Muangwong P; Tovanabutra C; Chomprasert K
J Gastrointest Oncol; 2018 Jun; 9(3):425-434. PubMed ID: 29998007
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer.
Brar H; Hogen L; Covens A
Cancer; 2017 May; 123(10):1751-1759. PubMed ID: 28117888
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
Matsuo K; Shimada M; Aoki Y; Sakamoto M; Takeshima N; Fujiwara H; Matsumoto T; Mikami M; Sugiyama T
Int J Cancer; 2017 Sep; 141(5):1042-1051. PubMed ID: 28524247
[TBL] [Abstract][Full Text] [Related]
6. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
[TBL] [Abstract][Full Text] [Related]
8. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
10. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
11. Total Laparoscopic Resection Surgery for a Cervical Carcinoma that Recurred in the Pelvic Sidewall After Radical Hysterectomy and Adjuvant Concurrent Chemoradiotherapy.
Kanao H; Aoki Y; Kato K; Matoda M; Okamoto S; Nomura H; Omatsu K; Utsugi K; Takeshima N
J Minim Invasive Gynecol; 2017; 24(6):899-900. PubMed ID: 28642025
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer.
Kobayashi Y; Ohara T; Wada Y; Okuda Y; Kondo H; Okuma Y; Suzuki N; Gomi H; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2009 Jun; 35(3):490-4. PubMed ID: 19527388
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).
Nakamura K; Kitahara Y; Satoh T; Takei Y; Takano M; Nagao S; Sekiguchi I; Suzuki M
World J Surg Oncol; 2016 Jun; 14(1):173. PubMed ID: 27356862
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study.
Kagabu M; Nagasawa T; Tatsuki S; Fukagawa Y; Tomabechi H; Takatori E; Kaido Y; Shoji T; Baba T
Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34072478
[No Abstract] [Full Text] [Related]
17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor.
Kim H; Park W; Kim YS; Kim YJ
J Gynecol Oncol; 2020 May; 31(3):e35. PubMed ID: 31912685
[TBL] [Abstract][Full Text] [Related]
19. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and U.S. perspectives.
Lee JY; Kwon JS; Cohn DE; Kim Y; Smith B; Lee TJ; Kim JW
Gynecol Oncol; 2016 Jan; 140(1):83-9. PubMed ID: 26548733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
